Trials / Recruiting
RecruitingNCT06695689
An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM303 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LM303 | Treatment with LM303 injection |
Timeline
- Start date
- 2024-10-17
- Primary completion
- 2026-10-01
- Completion
- 2027-10-01
- First posted
- 2024-11-19
- Last updated
- 2024-11-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06695689. Inclusion in this directory is not an endorsement.